Cavidi is Sweden’s leading supplier of viral load for HIV monitoring. Cavidi’s products enable efficient management of anti-HIV drugs (ARV therapy) so that people living with HIV can live a normal lifespan. Cavidi’s diagnostics reduce the cost of treatment and the spread of HIV. Cavidi also provides tools and kits for virus research to many of the world’s leading labs.
Cavidi is a Swedish biotech company founded as a spin-off from Uppsala University. Our expertise is based on understanding viruses and using this knowledge to create research tools and clinical diagnostics. Today our focus is on HIV but our methods and expertise can be applied to other viruses.
Cavidi’s head office is in Uppsala, Sweden and we have sales offices in South Africa, India and USA. Our customers include hospitals, patient clinics, private laboratories, the pharmaceutical industry and research institutions worldwide.
Cavidi is ISO13485 certified for quality management systems.
Board of Directors
Vice President, Partnering Peaxy, Inc. Massachusetts Institute of Technology, San Francisco Bay Area
With more than 30 years of C-suite and consulting experience, Dave has a track record of making growth happen in the life science, material science, clean tech, and consumer product industries. His skill set was built through 10 years in management in large corporations (Monsanto, P&G), 15 years in consulting (McKinsey, Technology Pathfinders, and now Business Model Innovations, LLC), and 10 years as CEO of three science-based start-ups (Mendel, Acumen, Kinestral). Dave’s experience spans the closing of nine financings, licensing deals worth more than $300 million, M&A deals exceeding $500 million, and the creation of three large joint ventures with Fortune 500 corporate partners.
Clas Källander, Founder
Senior Scientific Advisor, Nominated to the Board
Clas co-founded Cavidi Tech AB in 1984. He has served as Cavidi’s Director of R&D for 12 years. He also served for 10 years on Cavidi board of directors, having previously served on Cavidi Tech AB’s board. He also Chairs the Cavidi Scientific Advisory Committee. Clas is an Associate Professor of Medical Virology at Uppsala University and has authored more than 60 research publications.
John Reisky de Dubnic, Chairman
Cavidi investor and former CEO
John joined Cavidi after leading a management buyout in 2007, and served as CEO from 2009-2019. As CEO of Cavidi over 10 years he took the company from academic research lab through the successful development of the Ziva Analyzer system. John led the company through the transition from small development lab to a growing commercial diagnostics company. In this time he has a record of success including raising development capital over six equity rounds and loans from EIB and ALMI, successful automation of a novel technology, and securing key partnerships with multiple global industrial partners.
John has over 30 years experience in management, at United Technologies, Schindler, Turbec AB, and Schneider Electric. He holds a BSc. in Engineering from the University of Virginia, and a MBA from Darden School of Business.
Scientific Advisory Committee
Professor John Mills
Chairman Emeritus, Cavidi AB, SB MD FACP FRACP ARCPA, Association of American Scientists (AAAS), Fellow Infectious Disease Society of America, Member Australasian Society of HIV Medicine, Community service Chair, Research Committee, and Director, Prostate Cancer Foundation of Australia, also Managing Director, TissuPath Pty Ltd, Non-executive Director of GBS Venture Partners P/L and Non-executive Director of Phosphagenics Corp (ASX: POH).
Professor Suzanne Crowe
AM, Macfarlane Burnet Institute for Medical Research and Public Health: Head, Pathogenesis and Clinical Research Program Centre for Virology, Head of Flow Cytometry Laboratory, Head of Clinical Research Laboratory. Consultant Physician in Infectious Diseases and General Medicine, Alfred Hospital, Melbourne, Professor of Medicine and Infectious Diseases (Personal Chair), Monash University, Melbourne, NHMRC Principal Research Fellow, awarded Member of the Order of Australia (AM) for her service to medical research in HIV/AIDS medicine and infectious diseases.
Dr. Brendan Larder
Chair RDI Scientific Core Group. Dr Larder is one of the world’s leading experts in the fields of HIV drug resistance and pharmacogenomics. He holds a PhD in Virology from Cambridge University. Dr. Larder discovered HIV drug resistance. His seminal work on AZT resistance and its genetic basis published in Science in 1989. Dr. Larder has continued to pioneer understanding in the field, unraveling the genetic basis of resistance to several other HIV drugs and developing many of the laboratory techniques for studying HIV drug resistance, including phenotyping and genotyping methodologies.
Professor Anders Sönnerborg
Adjunct professor in infectious disease Virology at the Department of Medicine, Karolinska University Hospital, Sweden. Anders focuses on research concerning mechanisms of resistance and failure to improve HIV-specific immunity in HIV treatment. In vitro experiments in model systems combined with experimental analysis of well-defined patient populations.
Associate Professor Johan Lennerstrand
Associate professor Section of Virology, Department of Medical Sciences, Uppsala University and University Hospital, Uppsala, Sweden.
Founder and Director of R&D, CAVIDI AB
Scientific Affairs Manager, CAVIDI AB.
Most frequent questions and answers
No. Our goal is to create tests that are universally accessible to both developed and developing nations alike. Within that mandate, we must address the fact that three quarters of the world’s population live in resource-limited settings.
Many medical tests can only be run in highly advanced medical facilities. Cavidi’s vision is a world where proper medical tests are accessible to anyone who needs them. So we strive to produce state-of-the-art tests with a minimal resource footprint. This approach makes Cavidi tests globally applicable but particularly attractive in settings where resources are limited.
At Cavidi we try to develop test solutions that adhere to our ACCESS policy:
- Affordable in the context of resource-limited settings
- Clinically relevant to both the diseases and measurement parameters needed
- Comparable to similar tests used in developed nations with regard to accuracy and reliability
- Easy to run and read in the field
- Swifter at showing results
- Suited to the infrastructure-limitations of resource-limited settings